Cannatrek signs MoU to advance medicinal cannabis research
Cannatrek, an Australian vertically integrated plant-based medicine company, has signed a memorandum of understanding (MoU) with Mie University in Tsu, Japan, to forge an open collaboration focused on accelerating medical research into the use of cannabis. The strategic partnership marks the first-ever MoU for medicinal cannabis research between any Australian and Japanese organisation or government.
The MoU swiftly follows the Japanese Government’s recent change in stance towards the use of cannabis with the Lower House passing the bill to legalise the use of medical products made from cannabis in mid-November.
Cannatrek CEO Tommy Huppert said, “Cannatrek has the manufacturing capability to supply the highest quality of medicinal cannabis products for domestic and international markets via our Shepparton facility. The facility recently received Good Manufacturing Practice (GMP) accreditation, which further enhances export opportunities.”
Under the MoU, the framework for cooperation encompasses several key areas including agronomic research, training resources for clinicians, pharmaceutical supply chain, e-healthcare, navigating regulation and compliance, and connecting experts in the field.
New public health campaign to improve pregnancy outcomes
The Preterm Birth Prevention campaign 'See, Stop, Scan' aims to promote engagement...
Feedback sought on genomic-led cancer control
The framework is designed to guide health professionals, researchers, health services and policy...
Can you die from long COVID? The answer is not so simple
Nearly five years into the pandemic, COVID is feeling less central to our daily lives.
